Is the Vial You Received What the Label Says?

Most advice about buying medication online stops at the moment you pay. This picks up after that, because the FDA’s published concerns are overwhelmingly about what turns up in the box — including labels that name compounding pharmacies which do not exist, and labels naming real pharmacies that had nothing to do with the product inside.^[1] If your check was “the label names a pharmacy”, that check does not work.

The label is not evidence of who made it

The FDA has described fraudulent compounded semaglutide and tirzepatide sold in the United States carrying false information on the label. Two distinct patterns: pharmacies named on the label that the agency could not find because they are not real, and the names of genuine licensed pharmacies printed on products those pharmacies did not compound.^[1]

The second is the more unsettling of the two, because it defeats the obvious verification. You look up the pharmacy, it exists, it holds a real state license, everything checks out — and none of that says anything about the vial in your hand. The agency has one adverse event report tied to a product labeled as compounded tirzepatide from a pharmacy that did not compound it, with redness, swelling, pain and a lump at the injection site.^[1]

Looking up the pharmacy on the label tells you the pharmacy is real. It does not tell you the pharmacy made this.

The check that does work is to go the other way: contact the pharmacy or the telehealth company directly and ask them to confirm this order, this lot. FDA’s own guidance points patients to the compounder or the platform they bought from for exactly this kind of question.^[1] A seller that cannot connect a lot number to a named pharmacy has told you something important.

Counterfeits of the brand product too

This is not only a compounding story. The FDA has said it is aware of counterfeit Ozempic marketed in the United States. Counterfeits claim to be authentic while potentially containing the wrong ingredients, too little or too much active ingredient, none at all, or something harmful.^[1]

Buying the brand does not by itself remove this risk; buying the brand from a state-licensed pharmacy is what does. Our verification guide covers how to establish that a pharmacy is what it claims to be.

If it arrives warm, the answer is no

Injectable GLP-1 drugs need refrigeration, and their package inserts say so. The FDA has received complaints about compounded GLP-1s arriving warm, or with too little ice to have kept them cold in transit, and its recommendation is not to use a product that arrives that way.^[1]

• Open the box the day it lands, not the evening you plan to inject. A shipment that sat on a doorstep through an afternoon has already had the thing that matters happen to it.
• Photograph the ice pack and the box before you unpack. If you need to argue about a replacement, that photograph is the whole argument.
• Melted or missing ice is the finding, regardless of how the vial looks. Degraded product looks completely normal.
• Do not put it in the fridge and use it anyway. Chilling something afterward does not undo the excursion.

The dosing errors are their own category

The FDA has received multiple reports of adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide. These came from patients measuring and self-administering the wrong amount, and in some cases from clinicians miscalculating the dose.^[1]

There is a structural reason this happens with compounded product and not with a pen. A pen meters the dose; a vial and syringe ask you to produce it, from a concentration the pharmacy chose. Our unit converter exists for that arithmetic, and the safest version of it is having the prescriber write the dose in units for the exact concentration you were sent.

Separately, the agency has had reports involving doses beyond what the approved labeling describes — more product per dose, doses taken more often, or titration climbing faster than the label schedule.^[1] If a plan you have been given moves faster than the label, that is a question worth asking out loud before the next injection.

What the adverse event counts do and do not tell you

As of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.^[1] Those numbers get quoted a great deal, and they are almost always quoted wrongly.

They are not rates. There is no denominator here — nobody knows how many people took compounded GLP-1s over the same period, so no percentage can be built from them. And they are floors rather than totals, because federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to the FDA at all. The agency says plainly that events from compounded versions are likely underreported.^[1]

If something happens to you, the reporting route is MedWatch, and it takes a few minutes.^[1] Given that pharmacies in this category are not obliged to report, a patient report may be the only way a given problem is ever counted.